Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse
Benjamin P Trewin,Russell C Dale,Jessica Qiu,Melissa Chu,Niroshan Jeyakumar,Fionna Dela Cruz,Jane Andersen,Pakeeran Siriratnam,Kit Kwan M Ma,Todd A Hardy,Anneke van der Walt,Jeanette Lechner-Scott,Helmut Butzkueven,Simon A Broadley,Michael H Barnett,Stephen W Reddel,Fabienne Brilot,Tomas Kalincik,Sudarshini Ramanathan,Australasian MOGAD Study Group,Robert Adam,Ian Andrews,Jayne Antony,Patrick Aouad,Monica Badve,Joshua Barton,Heidi Beadnall,Stefan Blum,Michael Boggild,David A Brown,Jim Burrow,Katherine Buzzard,Ann Bye,Anita Cairns,Sophie Calvert,Shabeed Chelakkadan,Damian R Clark,Marzena J Fabis-Pedrini,Deborah Field,Anthony Fok,Clare L Fraser,Victor Sc Fung,Justin Garber,Serge Geara,Deepak Gill,Sachin Gupta,Simon Hawke,Andrew Pd Henderson,Nevin A John,Dean L Jones,Hannah F Jones,Allan Kermode,Matthew Kiernan,Trevor Kilpatrick,Andrew J Kornberg,Mitchell Lawlor,Fiona Xz Lee,Richard J Leventer,Vivien Li,Simon Ling,Ganesha Liyanage,Joseph A Lopez,Stephen Malone,Mark P Marriot,Pamela McCombe,Alan McDougall,Manoj P Menezes,Vera Merheb,Christina Miteff,Mastura Monif,Gopinath Musuwadi Subramanian,Ai-Lan Nguyen,Gina O'Grady,John O'Neill,Robert Ouvrier,Mark Paine,John Parratt,Sekhar Pillai,Jane Prosser,Sean Ds Riminton,Izanne Roos,Jennifer Sandbach,Ingrid E Scheffer,Ubaid Shah,Neil Shuey,Adriane Sinclair,Mark Slee,Claire G Spooner,Ian Sutton,Sanjay Swaminathan,Esther Tantsis,James Thomas,Terrence Thomas,Julia Thompson,Christopher Troedson,Steve Vucic,Justine Wang,Tyson Ware,Richard Webster,Ming Wei Lin,Owen White,Wei Yeh,Con Yiannikas,Eppie M Yiu,Michael Zong
DOI: https://doi.org/10.1136/jnnp-2024-333463
2024-05-16
Abstract:Background: We sought to identify an optimal oral corticosteroid regimen at the onset of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), which would delay time to first relapse while minimising cumulative corticosteroid exposure. Methods: In a retrospective multicentre cohort study, Cox proportional hazards models examined the relationship between corticosteroid course as a time-varying covariate and time to first relapse. Simon-Makuch and Kaplan-Meier plots identified an optimal dosing strategy. Results: We evaluated 109 patients (62 female, 57%; 41 paediatric, 38%; median age at onset 26 years, (IQR 8-38); median follow-up 6.2 years (IQR 2.6-9.6)). 76/109 (70%) experienced a relapse (median time to first relapse 13.7 months; 95% CI 8.2 to 37.9). In a multivariable model, higher doses of oral prednisone delayed time to first relapse with an effect estimate of 3.7% (95% CI 0.8% to 6.6%; p=0.014) reduced hazard of relapse for every 1 mg/day dose increment. There was evidence of reduced hazard of relapse for patients dosed ≥12.5 mg/day (HR 0.21, 95% CI 0.07 to 0.6; p=0.0036), corresponding to a 79% reduction in relapse risk. There was evidence of reduced hazard of relapse for those dosed ≥12.5 mg/day for at least 3 months (HR 0.12, 95% CI 0.03 to 0.44; p=0.0012), corresponding to an 88% reduction in relapse risk compared with those never treated in this range. No patient with this recommended dosing at onset experienced a Common Terminology Criteria for Adverse Events grade >3 adverse effect. Conclusions: The optimal dose of 12.5 mg of prednisone daily in adults (0.16 mg/kg/day for children) for a minimum of 3 months at the onset of MOGAD delays time to first relapse.